FITC Anti-HLA-DR 抗体 [MEM-12] (ab28323)
Key features and details
- FITC Mouse monoclonal [MEM-12] to HLA-DR
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Related conjugates and formulations
製品の概要
-
製品名
FITC Anti-HLA-DR antibody [MEM-12]
HLA-DR 一次抗体 製品一覧 -
製品の詳細
FITC Mouse monoclonal [MEM-12] to HLA-DR -
由来種
Mouse -
標識
FITC. Ex: 493nm, Em: 528nm -
アプリケーション
適用あり: Flow Cytmore details -
種交差性
交差種: Human -
免疫原
Tissue, cells or virus corresponding to Human HLA-DR. Thymocyte membrane
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. -
バッファー
pH: 7.4
Preservative: 0.097% Sodium azide
Constituents: PBS, 0.2% BSA -
Concentration information loading...
-
精製度
Protein A purified -
特記事項(精製)
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC). The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary. -
ポリ/モノ
モノクローナル -
クローン名
MEM-12 -
アイソタイプ
IgG1 -
軽鎖の種類
kappa -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab28323の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Flow Cyt |
Use at an assay dependent concentration.
Use 20ul for 10^6 human blood cells or 100ul of whole blood. ab106163 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
特記事項 |
---|
Flow Cyt
Use at an assay dependent concentration. Use 20ul for 10^6 human blood cells or 100ul of whole blood. ab106163 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
ターゲット情報
-
機能
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. -
配列類似性
Belongs to the MHC class II family.
Contains 1 Ig-like C1-type (immunoglobulin-like) domain. -
翻訳後修飾
Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective. -
細胞内局在
Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation. - Information by UniProt
-
参照データベース
- Entrez Gene: 3122 Human
- Omim: 142860 Human
- SwissProt: P01903 Human
- Unigene: 520048 Human
-
別名
- DASS-397D15.1 antibody
- DR alpha chain antibody
- DR alpha chain precursor antibody
see all
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (2)
ab28323 は 2 報の論文で使用されています。
- Lundholm M et al. Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions. Sci Rep 5:15651 (2015). Flow Cyt ; Human . PubMed: 26503803
- Horejsí V et al. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. Tissue Antigens 28:288-97 (1986). PubMed: 2435017